Listen to this article here
|
The Food and Drug Administration is now expected to authorize two COVID-19 vaccines for America’s youngest children.
On Wednesday, an FDA advisory committee voted 21-0 that the benefits of Moderna’s MRNA, +0.32% two-dose vaccine for children between the ages of 6 months old and 5 years old outweigh the risks.
Long Covid could plague our community worse than others
According to Market Watch, the committee also voted 21-0 in favor of BioNTech BNTX, -0.09% and Pfizer’s PFE, +0.45% three-dose COVID-19 vaccine for children between the ages of 6 months old and 4 years old. (The dosing for both vaccines is different than it is for adults.)
The FDA is not required to follow the advice of the advisory committee but it often does. Once the regulator makes its decision on both vaccines, the next step in the regulatory process is getting approved from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices and then finally a sign-off from CDC director Dr. Rochelle Walensky.